Stryker (SYK)
(Delayed Data from NYSE)
$369.02 USD
-0.84 (-0.23%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $369.15 +0.13 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$369.02 USD
-0.84 (-0.23%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $369.15 +0.13 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum D VGM
Zacks News
Is a Surprise in Store for ResMed (RMD) in Q4 Earnings?
by Zacks Equity Research
Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.
McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
IDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.
What's in Store for Express Scripts (ESRX) in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.
Baxter International (BAX) Q2 Earnings: What's in Store?
by Zacks Equity Research
Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.
Varian Medical (VAR) Q3 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Varian Medical Systems' (VAR) oncology business strength might drive its performance in Q3.
Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.
Is a Surprise in Store for CR Bard (BCR) in Q2 Earnings?
by Zacks Equity Research
Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.
GNC Holdings (GNC) Q2 Earnings: Disappointment in the Cards?
by Zacks Equity Research
We do not expect GNC Holdings (GNC) to beat estimates in Q2 earnings on account of a tough competitive landscape and currency headwinds.
Edwards Lifesciences (EW) Q2 Earnings: A Surprise in Store?
by Zacks Equity Research
Edwards Lifesciences (EW) will likely ride high in Q2 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve space.
Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.
Align Technology Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $157.86 on Jul 17, eventually closing a bit lower at $156.21.
Stryker Poised on Solid Product Portfolio and Acquisitions
by Zacks Equity Research
On Jul 17, we issued an updated research report on Kalamazoo, MI-based Stryker Corporation (SYK), one of the largest medical device companies in the global orthopedic market.
5 Stocks with Impressive Sales Growth Worth Investing In
by Zacks Equity Research
Sales are often more closely monitored than earnings when assessing the growth of a business.
Company News for June 20, 2017
by Zacks Equity Research
Companies in the News are: RICE,EQT,RIGL,NVDQ,SYK,VRX
Novadaq Technologies (NVDQ) Stock Soars 95% on Stryker Acquisition Deal
by Megan Sanks
On Monday, NOVADAQ Technologies Inc. (NVDQ) announced that Stryker Corporation (SYK) has agreed to acquire the company for $11.75 per share in cash, putting NOVADAQ's total worth at $701 million.
Stryker (SYK) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Stryker Corporation (SYK), headquartered in Kalamazoo, MI, scaled a new 52-week high of $141.21 on May 25, eventually closing a little lower at $140.85.
The Zacks Analyst Blog Highlights: Kraft Heinz, Nike, Stryker, DISH Network, TD Ameritrade and Freeport-McMoRan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Kraft Heinz, Nike, Stryker, DISH Network, TD Ameritrade and Freeport-McMoRan
Top Research Reports for Today: KHC, NKE, SYK & More
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Kraft Heinz (KHC), Nike (NKE) and Stryker (SYK).
Should You Sell Stryker (SYK) Stock Before Earnings?
by Zacks Equity Research
Stryker (SYK) might report a beat in the to be reported quarter on the back of its favorable Zacks Rank and positive Earnings ESP.
Medical Product Stocks Earnings on Apr 25: SYK, EW, LH
by Zacks Equity Research
Medical is one of the broader sectors among the 16 Zacks sectors that are expected to report earnings growth in the first quarter.
Will Stryker (SYK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Stryker Corporation (SYK), a leading player in the medical technology space, is set to report first-quarter 2017 results on Apr 25 after the bell.
Stryker Launches MAKO Robotic-Arm for Knee Anthroplasty
by Zacks Equity Research
Stryker Corporation (SYK) recently announced the commercial launch of a robotic-arm assisted total knee arthroplasty application based on its flagship MAKO System.
Why Is Stryker Corp (SYK) Up 5% Since the Last Earnings Report?
by Zacks Equity Research
Stryker Corp (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance
by Zacks Equity Research
Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate by 2 cents.